Products Companion animals

26 August 2021

AusCann to market its anti-inflammatory for dogs’ skin

by Katie Pfaff

Australia-based AusCann Group Holdings submitted for approval with its country’s regulatory body for its DermaCann CBD-based anti-inflammatory for dogs with the dermatological disease. The company plans to market the product in US states that allow CBD products.

DermaCann is used to treat canine atopic dermatitis and was found to be safe and efficacious at lessening inflammatory skin lesions (51%) during a randomized, placebo-controlled, double-blind study. The product used plant-based ingredients, including high-grade cannabidiol.

Dermatological disease is relatively common in dogs, and the market is estimated to be valued at $1.5 billion worldwide. Commercialization is planned in South Africa and in the United States, where states allow for cannabinoids for treatment of animals without registration.

Source: https://www.prnewswire.com/news-releases/auscann-commences-australian-product-registration-with-first-regulatory-filing-for-dermacann-301336930.html

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

Dislike0

EVENTS

Edrapublishing

About Us Authors Contact Us Legal Notes Privacy Search

Top

AusCann to market its anti-inflammatory for dogs’ skin

by Katie Pfaff

Comments

List

Add

Tag

Related Articles

08 December 2023
Retrospective evaluation of the incidence of gastrointestinal bleeding in dogs receiving ophthalmic nonsteroidal anti-inflammatory drugs

Retrospective evaluation of the incidence of gastrointestinal bleeding in dogs receiving ophthalmic nonsteroidal anti-inflammatory drugs

15 June 2023
Prophylactic omeprazole in dogs treated for acute thoracolumbar intervertebral disc extrusion

Prophylactic omeprazole in dogs treated for acute thoracolumbar intervertebral disc extrusion

15 February 2023
Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis in dogs

Sustained release of locally delivered celecoxib provides pain relief for osteoarthritis in dogs

11 October 2022
Veterinary pain management market to hit $2.5B

Veterinary pain management market to hit $2.5B

07 July 2022
Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses

Pharmacokinetics of grapiprant and effects on TNF-alpha concentrations following oral administration to horses

More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Newsletter

News of interest

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

One Committed and Caring NC State Veterinary Student, So Many Choices

Philanthropic Support and Specialized Surgery Saves Dog with Oral Tumor

EVENTS